These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 26991962

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M, Middeldorp S, Coppens M.
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE, Merino JL, Barrios V.
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV, O'Callaghan JM, Handa A.
    Vasc Health Risk Manag; 2016 Apr; 12():329-35. PubMed ID: 27563246
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Edoxaban tosylate.
    Am J Cardiovasc Drugs; 2011 Apr; 11(2):129-35. PubMed ID: 21446778
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E.
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [Abstract] [Full Text] [Related]

  • 18. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM, Finks SW.
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [Abstract] [Full Text] [Related]

  • 19. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY, ENSURE-AF investigators.
    Lancet; 2016 Oct 22; 388(10055):1995-2003. PubMed ID: 27590218
    [Abstract] [Full Text] [Related]

  • 20. Edoxaban: an update on the new oral direct factor Xa inhibitor.
    Bounameaux H, Camm AJ.
    Drugs; 2014 Jul 22; 74(11):1209-31. PubMed ID: 25034361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.